Literature DB >> 26523730

Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study.

Eric D Peselow1, Steven Clevenger, Waguih W IsHak.   

Abstract

Mood stabilizers are used clinically for the management of bipolar disorder. Prophylactic therapy with mood stabilizers is the primary treatment for preventing depressive and manic relapses in bipolar patients once they are stabilized. In this study, we examined the relative efficacy of the three most commonly used mood-stabilizing agents: lithium (Li), valproic acid (VPA), and carbamazepine (CBZ), in preventing relapse episodes. A total of 225 patients with bipolar disorder were included in the present analysis. Patients taking Li, VPA, or CBZ were followed up for up to 124 months, until suffering a manic, mixed, or depressive episode (relapse), or until the end of the study/study termination (no relapse), whichever came first. The median unadjusted survival time was 36 months for patients taking VPA, 42 months for patients taking CBZ, and 81 months for patients taking Li. These results indicate that patients stayed longer on Li, suggesting that it might have been better tolerated than either CBZ or VPA. χ-Analysis showed that patients taking Li were significantly less likely to experience relapse during the observational period than patients taking either VPA or CBZ (P<0.05). A Cox regression model showed that the hazard of experiencing relapse was significantly predicted by the total number of depressive (P=0.007) and manic symptoms (P=0.02) assessed before the observation period. In addition, after controlling for symptom covariates, the hazard of experiencing relapse was 1.66 times (95% confidence interval 1.03-2.67) or 66% higher for patients taking VPA compared with patients taking Li (P=0.037). Although the hazard of experiencing relapse was higher for patients taking CBZ compared with those taking Li, the risk was not elevated by a significant amount. Notwithstanding the limitations of the naturalistic design of this study, the differences in relapse prevention and survival time observed in these medications show Li fairing relatively better in prophylactic therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26523730     DOI: 10.1097/YIC.0000000000000097

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  5 in total

1.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

Review 2.  Efficacy of Carbamazepine and Its Derivatives in the Treatment of Bipolar Disorder.

Authors:  Anna Grunze; Benedikt L Amann; Heinz Grunze
Journal:  Medicina (Kaunas)       Date:  2021-04-30       Impact factor: 2.430

3.  Long-term response to mood stabilizer treatment and its clinical correlates in patients with bipolar disorders: a retrospective observational study.

Authors:  Sung Woo Ahn; Ji Hyun Baek; So-Yung Yang; Yongkang Kim; Youngah Cho; Yujin Choi; Kounseok Lee; Taesung Park; Kyung Sue Hong
Journal:  Int J Bipolar Disord       Date:  2017-07-09

4.  Compliance with the guidelines for laboratory monitoring of patients treated with lithium: A retrospective follow-up study among ambulatory patients in the Netherlands.

Authors:  Mariëtte Nederlof; Toine Cg Egberts; Liesbeth van Londen; Maurits Cfj de Rotte; Patrick C Souverein; Ron Mc Herings; Eibert R Heerdink
Journal:  Bipolar Disord       Date:  2019-01-02       Impact factor: 6.744

5.  Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine.

Authors:  Evangelos Kouremenos; Chrysa Arvaniti; Theodoros S Constantinidis; Ermioni Giannouli; Nikolaos Fakas; Themistoklis Kalamatas; Evangelia Kararizou; Dimitrios Naoumis; Dimos D Mitsikostas
Journal:  J Headache Pain       Date:  2019-12-13       Impact factor: 7.277

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.